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Abstract:  As  an  early  response  to  infection,  cells  induce  a  profile  of  the  early 
inflammatory  proteins  including  antiviral  cytokines  and  chemokines.  Two  families  of 
transcriptional  factors  play  a  major  role  in  the  transcriptional  activation  of  the  early 
inflammatory  genes:  The  well-characterized  family  of  NFkB  factors  and  the  family  of 
interferon regulatory factors (IRF). The IRFs play a critical role in the induction of type I 
interferon (IFN) and chemokine genes, as well as genes mediating antiviral, antibacterial, 
and inflammatory responses. Type I IFNs represent critical components of innate antiviral 
immunity. These proteins not only exert direct antiviral effects, but also induce maturation 
of dendritic cells (DC), and enhance functions of NK, T and B cells, and macrophages. 
This review will summarize the current knowledge of the mechanisms leading to the innate 
antiviral  response  with  a  focus  on  its  role  in  the  regulation  of  HIV-1  infection  and 
pathogenicity. We would like this review to be both historical and a future perspective.  
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1. Introduction 
The  ability  of  the  host  to  detect  invasion  by  a  pathogenic  intruder  and  to  activate  defense 
mechanisms to eliminate infection is essential for survival. The innate immune response has developed 
as a rapid and regulated defense mechanism against invading pathogens. Remarkable progress has 
been made in recent years into the identification of cellular receptors detecting the invading pathogens 
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as well as in understanding the signaling pathways leading to the induction of Type I IFN genes and 
inflammatory cytokines. It has been shown that the recognition of an invading pathogenic organism 
can occur upon binding of viral nucleic acids or envelope proteins to specific membrane associate 
receptors,  denoted  Toll-like  (TLR)  receptors,  which  can  recognize  conserved  patterns  of  proteins, 
lipoproteins, and viral RNA [1]. In addition, cytoplasmic sensors can recognize viral RNA or DNA in 
the B configuration of the invading pathogens. In addition, the cellular polymerase III that converts 
cytoplasmic DNA into 5’phosphorylated RNA recognized by RIGI is also an important component of 
the  innate  virus  detection  system.  The  binding  of  viral  ligands  to  host  sensors  induces  multiple 
signaling pathways that activate cellular transcription factors controlling the expression of a diverse set 
of genes, which in turn coordinate both the innate and adaptive immune responses. Although cascades 
of multiple kinases and ubiquitination steps usually mediate activation of these transcription factors, 
their functional diversity is modulated by interaction with other transcription factors and cofactors. 
Indeed,  these  regulatory  networks  are  critical  components  of  the  host  defense  against  invading 
pathogens, including viruses.  
In  response  to  infection,  cells  induce  early  inflammatory  proteins  including  type  I  IFN  and 
inflammatory cytokines. Two families of transcriptional factors play a major role in the stimulation of 
expression  of  these  proteins:  the  well-characterized  family  of  NFkB  factors  and  the  family  of 
interferon regulatory factors (IRF). The IRFs play a critical role in the induction of Type I interferon 
(IFN)  and  chemokines  as  well  as  proteins  mediating  antiviral,  antibacterial,  and  inflammatory 
responses [2,3]. Type I IFNs are critical components of the innate antiviral response. These proteins 
not only exert direct antiviral effects, but also induce maturation of dendritic cells (DC), recruitment of 
the immune cells to the sites of infection, and enhance the functions of macrophages, NK, T and B 
cells, and macrophages [4]. The importance of Type I IFN to the activation of effector cell populations 
and  adaptive  immunity  is  also  emerging.  This  chapter  will  review  the  current  knowledge  of  the 
molecular  mechanisms  leading  to  the  innate  antiviral  response  with  a  focus  on  its  role  in  HIV-1 
infection. We would like this review to have both a historical and a future perspective. 
2. Transcription Factors of the IRF Family 
The IRFs are transcriptional mediators of virus, bacteria and IFN-induced signaling pathways and 
as such play a critical role in antiviral defense, immune response, cell growth regulation and apoptosis. 
To date, nine human cellular IRF genes (IRF-1, IRF-2, IRF-3, IRF-4/Pip/ICSAT, IRF-5, IRF-6, IRF-7, 
ICSBP/IRF-8 and ISGF3γ/p48/IRF-9), as well as virus-encoded analogues of cellular IRFs have been 
identified  [5,6].  These  factors  can  function  as  transcriptional  activators  (e.g.,  IRF-1,  IRF-3,  and  
IRF-9),  repressors  (e.g.,  IRF-8)  or  both  (e.g.,  IRF-2,  IRF-4,  IRF-5).  They  all  share  significant 
homology in the N-terminal 115 amino acids, which comprise the DNA-binding domain, characterized 
by  five  tryptophan  repeats.  Three  of  these  repeats  contact  DNA  with  specific  recognition  of 
5’GAAA3’ and 5’AANNGAAA3’ sequences [7]. However, the unique function of a particular IRF is 
accounted  for  by  cell  type-specific  expression,  intrinsic  transactivation  potential,  and  an  ability  to 
interact with other members of the IRF family or other transcription factors and co-factors [8]. All 
IRFs, except IRF-1 and IRF-2, contain the IRF- associated domain (IAD) in the 3’ terminal part of the 
protein, which mediates these interactions.  Viruses 2011, 3                         
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The first IRFs, IRF-1 and IRF-2, were identified through their ability to bind to the virus responsive 
element (VRE) of the IfnB gene and were proposed to function as an activator and repressor of the IfnB 
gene, respectively [9]. However, homozygous deletion of IRF-1 in mice did not impair activation of 
IfnA or IfnB genes in infected mouse embryo fibroblasts (MEFs), while dsRNA-mediated induction of 
Type I IFN was down-regulated [10]. Subsequent studies have revealed that IRF-1 is involved in a 
broad spectrum of antiviral defenses mediated by IFN-γ by activation of the IfnG genes. Furthermore, 
analysis of the repertoire of lymphoid cells from mice devoid of IRF-1(Irf1 null) has shown defects in 
the maturation of CD8+ T cells as well as a defective Th1 response, impaired production of IL-12 in 
macrophages, and defective NK cell development. 
Although IRF-1 stimulates expression of the IfnG gene, it does not have a critical role in viral 
mediated stimulation of Type I IfnB genes. However, subsequent identification of three IRFs (IRF-3, 
IRF-5  and  IRF-7)  showed  that  they  are  direct  transducers  of  virus-mediated  signaling  and 
demonstrated their crucial role in the expression of Type I Ifn genes and some chemokines [6,11–13]. 
The identification of IRF-3 and IRF-7 and their role in the transcriptional activation of type I Ifn genes 
had a major impact on the understanding of the molecular mechanism of the pathogen-induced innate 
antiviral response [14–17]. In human cells, multiple spliced variants of these IRFs can be detected, and 
some of these variants can function as dominant negative mutants. In infected cells, the ubiquitously 
expressed  IRF-3  mediates  induction  of  IFNβ  and  of  some  IFN  induced  genes  (ISG),  whereas 
expression of IRF-5 and IRF-7 is limited largely to lymphoid cells, where they are required for the 
expression of the IfnA genes [3,14]. Reconstitution of IRF-5 or IRF-7 expression in infected fibroblasts 
that express only IFNβ confirmed expression of IFNα subtypes [18]. In many cells, IRF-3 and IRF-7 
are involved in the amplification of the interferon response: antiviral response is generally induced 
through  two  sequential  steps:  (1)  virus  activates  IRF-3,  which  leads  to  synthesis  of  IFNβ.  
(2)  IFNβ  stimulates  transcription  of  IRF-7,  which  results  in  synthesis  of  IFNα  and  further 
enhancement of IFNβ synthesis [12]. 
High constitutive levels of both IRF-5 and IRF-7 were detected in plasmacytoid dendritic cells 
(PDC), which are high IFNα producers [19,20]. Subtypes of IfnA genes induced by IRF-5 and IRF-7 in 
B  cells  are  distinct,  indicating  that  these  two  factors  have  both  essential  and  non-redundant  
functions [21]. IRF-7 expression is critical for induction of IfnA genes both in vitro and in vivo. Virus 
infection or CpG DNA was not able to stimulate expression of Type I Ifn genes in Irf7−/− mice. The 
authors concluded, therefore, that IRF-7 is the master regulator of type I IFN [22], although residual 
IFN production, mediated by IRF-3, could still be induced in cells of non-lymphoid origin. In contrast 
Irf5−/−  mice  showed  not  only  a  decrease  in  virus  mediated  induction  of  Type  I  IFN,  but  also  a 
significant decrease in expression of inflammatory cytokines such as TNFα, IL-6 and IL-12 [23,24]. 
Furthermore, recent data indicate that IRF-5 has a critical role in the development of TH-1 responses to 
Leishmania donovani infection [25] as well as in the differentiation and function of B cells [26] and 
macrophages [27]. Thus, while the role of IRF-7 is critical for the innate antiviral response, IRF-5 
function is broader, and can mediate the cross-talk between innate and adaptive immune responses.  
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2.1. The Viral IRF: KSHV-Encoded Viral IRF 
Kaposi’s sarcoma-associated herpes virus (KSHV) is a member of the γ herpes virus family and is 
genetically similar to EBV and monkey Herpes Virus Saimiri (HVS) [28]. Sequence analysis of the 
KSHV genome revealed the presence of about 80 open reading frames (ORFs) and a number of ORFs 
showing homology to cellular genes including a cluster of four ORFs with homology to the cellular 
IRF family transcription factors [29], three of which have been cloned and characterized. The open 
reading frame 9 of KSHV genome (ORF K9)-encoded vIRF-1, has been studied most extensively and 
was shown to inhibit both virus-mediated induction of Type I Ifn genes and IFN-induced genes (ISG) 
[30–34].  
vIRF-2 (ORF K11.1) encodes a small nuclear protein (163 aa) that unlike the cellular IRFs, binds 
dsRNA-activated protein kinase (PKR), inhibits its kinase activity and blocks the phosphorylation of 
the PKR substrate, eukaryotic translation initiation factor 2α [34,35].  
vIRF-3/LANA2, encoded by ORFs K10.5 and K10.6 [36,37], is a multifunctional nuclear protein 
constitutively  expressed  in  KSHV-positive  B  cell  lymphoma  cells  (PEL)  and  Castleman’s  disease 
tumors [38]. The vIRF-3 protein binds to IRF-3, IRF-7 and IRF-5 [37,38] vIRF-3 also interacts with 
two tumor suppressor genes, p53 and MM-1 [39]. 
2.2. IRF Mediated Cross Talk between Innate and Adaptive Immune Response 
The observation that some IRFs also have an essential role in the differentiation and function of 
lymphoid cells emerged mainly from a large number of studies in genetically modified mice. Thus, 
IRF-1 participates not only in the induction of the IfnG gene, but also in several autocrine loops that 
induce  and  enhance  the  Th1  response  [40,41].  IRF-4  has  been  also  associated  with  Th  cell 
development and the differentiation of B cells to plasma cells [42]; Irf4−/− mice show a complete 
absence  of  plasma  cells  [43].  Irf8−/−  mice  show  major  defects  in  CD8+DC  and  plasmacytoid 
dendritic cells (PDC). These mice also display increased susceptibility to infection, which is due to a 
defect in the Th1 immune response and an inability to express IL-12 [44,45]. IRF-3 and IRF-7 play 
essential roles in the antiviral response, however IRF-7 also has an important role in the differentiation 
of monocytes to macrophages [46]. The Th1 and Th2 responses of Irf3−/− or Irf7−/− mice have yet to 
be characterized, however a DNA-mediated Th1 immune response was enhanced by co-expression of 
IRF-3 and IRF-7 [47]. IRF-5 plays an important role in B cell differentiation and function in vitro. 
Infected B  cells over expressing  IRF-5 show up-regulated  expression of several immune response 
genes, including CD80, MyD88 and ISG [21], and IRF-5 promotes macrophage polarization and TH-1 
response [25,27]. Irf5−/− mice show  a defect in differentiation of  B cells to plasma cells and an 
attenuated response to antigenic stimulation [26]. IRF-9 is an important component of the ISGF-3 
complex  with  an  essential  role  in  the  type  I  IFN  signaling  pathway  and  induction  of  many  ISGs 
including IRF-7 and IRF-5 [48]. The Ifr9−/− mice show a significant defect in Type I IFN signaling 
and share many characteristics with the Stat1−/− and InfR1−/− mice. These mice are also predicted to 
be defective in expression of many ISGs including both IRF-7 and IRF-5. However, whether they 
show modulation of the adaptive immune response similar to Irf5−/− mice has yet to be evaluated. 
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3. Induction of the Antiviral Response 
In has been shown recently that both membrane bound receptors and cytoplasmic cellular sensors 
recognize  viral  infection.  Although  the  signaling  pathways  induced  by  these  receptors/sensors  are 
distinct, they generally result in activation of two members of the IRF family, IRF-3 and IRF-7. The 
majority  of  uninfected  cells  express  IRF-3  constitutively,  which  is  present  predominantly  in  the 
cytoplasm. Upon virus-induced phosphorylation at the carboxyl terminal serines, IRF-3 translocates to 
the  nucleus,  where  it  forms  a  transcriptional  complex—the  enhanceosome—with  the  transcription  
co-activator p300/CBP, NfkB and Jun, which subsequently binds to interferon responsive elements 
(IRF-E) in the promoters of IfnB gene [49]. IRF-7 can be activated by a similar pathway and is a 
member  of  a  multicomponent  complex,  binding  to  the  promoters  of  IfnA  genes  [13,50,51].  IRF-5 
shows  structural  and  functional  features  distinct  from  IRF-3  and  IRF-7.  The  IRF-5  polypeptide 
contains two nuclear localization signals that are not present in IRF-3 or IRF-7, and low levels of 
nuclear IRF-5 can be detected in uninfected cells. Activation of IRF-5 appears to be virus-specific, and 
it can be phosphorylated in NDV- or VSV- infected but not in Sendai virus-infected cells or in poly IC 
treated cells [6]. 
3.1. The Role of IRF in Toll Receptor Mediated Antiviral Pathway 
Understanding the mechanism by which cells detect invading pathogens was significantly advanced 
by the observation that this immune response is initiated by Toll like receptors (TLR) [52,53]. The 
TLR are Type I transmembrane protein receptors expressed in endosomes that recognize conserved 
motifs  unique  to  pathogens,  denoted  as  pathogen-associated  molecular  patterns  (PAMPS).  The 
presence  of  dsRNA,  which  has  been  considered  the  common  signature  of  virus  infected  cells,  is 
recognized by TLR3, while ssRNA activates TLR7/8, and unmethylated dsDNA activates TLR9. The 
binding  of  viral  nucleic  acids  to  their  respective  TLR  induces  signaling  pathways  leading  to  the 
activation of IRF and NFkB. Some TLR, like TLR2 can form homo or heterodimers, which alters the 
specificity of the ligand binding. With the exception of TLR3, activation of all TLR family members is 
dependent on the adaptor MyD88 [17]. Upon ligand activation, the intracellular part of TLR-TIR binds 
a tetramer of MyD88, and the signaling pathway is initiated by recruitment of IRAK1 and IRAK4, 
which are autophosphorylated and form a complex with the E3 ubiqitin ligase TRAF6 [54]. This can 
activate  mitogen  activated  protein  kinase  and  lead  to  the  activation  of  NFkB,  which  binds  to  the 
promoters of inflammatory genes such as IL-6 and TNFα or leads to the activation of IRF [17,55]. 
The expression of TLR is cell type specific. Thus the PDC, which represent the major source of 
Type I IFN, (largely IFNα), constitutively express TLR7/8 and TLR9 as well as relatively high levels 
of IRF-5 and IRF-7 [56]. In contrast, TLR3 signaling is distinct, it does not associate with MyD88, and 
binding  of  dsRNA  to  the  TLR3  receptor  activates  IRF-3  through  the  TRIF  adaptor  [57].  Two  
non-canonical  IKB  kinases,  IKKε  and  TBK-1,  have  been  implicated  in  the  phosphorylation  and 
activation of IRF-3 and IRF-7 in cultured human cell lines in vitro [58]. Activated IRF-3 dimerizes and 
binds to p300/CBP co activators [49], translocates to the nucleus and activates transcription of the IfnB 
gene  and  some  ISGs  in  IFN-independent  manners  [59].  Both  IKKε  and  TBK-1  kinases  also Viruses 2011, 3                         
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phosphorylate IKBα, but only on serine 36, which does not lead to the degradation of IKBα by the 
ubiquitination pathway or to activation of NFkB [60].  
The TLR adaptor, TRIF, is a potent activator of the IfnB promoter. Mice that are Trif- deficient or 
have a mutation in the Trif gene [61] have a profound defect in IRF-3 activation and fail to produce 
IFNβ. In addition, activation of IRF-3 and stimulation of IfnB and Rantes in infected or LPS-treated 
cells does not occur in TBK-1-deficient cells. It is noteworthy that whereas TRIF was shown to be 
solely  responsible  for  the  TLR3-  mediated  activation  of  IRF-3,  activation  by  TLR4  requires  an 
additional adaptor protein MAL [62]. Taken together, these results indicate that the initial signaling 
events leading to the activation of TBK-1 by TLR3 and TLR4 may not be identical. However, there is 
strong evidence that IRF-3 plays an essential role in the antiviral response. First, ubiquitous expression 
in most of the cell types, allows stimulation of the antiviral response and synthesis of IFNβ in a variety 
of infected cell types [14]. Second, even low levels of autocrine or paracrine IFNβ stimulate expression 
of Irf7 and Irf5 and triggers amplification of the antiviral response [12,63]. Finally, the observation 
that many viruses prevent the induction of Type I IFN by targeting the function of IRF-3, underlines a 
central role for IRF-3 in the induction of the antiviral response [64]. 
TLR7/8 and TLR9 are an evolutionarily related subgroup within the TLR family [65]. Both of these 
receptors are expressed in PDC, and act intracellularly in association with endosomes in a MyD88 
dependent fashion. The TLR7/8 and TLR9 signaling pathway activates IRF-7 and IRF-5, (but not  
IRF-3). While the unmethylated CpG DNA [66] specifically stimulates TLR9, single stranded (ss) 
viral RNA and synthetic siRNA are recognized by TLR7 and TLR8 [67]. In mice, TLR7 is activated 
by  infections  with  ssRNA  viruses,  including  influenza  virus  and  vesicular  stomatitis  virus  (VSV) 
[67,68]. The activation of MyD88 pathways is initiated by the assembly of a multicomponent complex 
containing MyD88 tetramers, IRAK1 and IRAK4, TRAF6 and IRF-7 and or IRF-5. Activation of these 
two IRFs requires ubiqiutination by TRAF6 and phosphorylation by a not yet well defined kinase. 
Thus while IRF-7 can be activated both by TRIF and MyD88 pathways, IRF-5 is activated only by 
TLR7  and  TLR9,  and  the  activation  is  dependent  on  MyD88  and  K63  ubiquitination  by  TRAF6 
[69,70]. 
3.2. The Role of CARD-containing Proteins in Activation of IRF-3 
dsRNA,  generated  as  an  intermediate  during  virus  replication,  can  be  also  recognized  by 
cytoplasmic sensors. Two closely related intracellular RNA helicases, Rig-I and MDA5, which are 
ubiquitously expressed in nearly all cell types, can recognize dsRNA and 5’triphosphorylated RNA. 
Both helicases contain two N’ terminal caspase-recruiting domains (CARD) that activate downstream 
signaling pathways and a C-terminal DExD/H helicase domain that binds RNA. Signaling by Rig-I is 
mediated through downstream interaction with the adaptor protein IPS-1/MAVS. Both sensors contain 
CARD domains, and conformational changes occurring upon RNA binding permit these domains to 
interact with the CARD domain of an adaptor IPS-1/ MAVS. This protein is localized on the outer 
mitochondrial membrane and this association is critical for its activity. IPS-1 activates TBK-1 and 
IKKe that leads to the activation of IRF-3, IRF-7 and NFkB. The IPS-1-dependent signaling is an 
essential feature of host immunity to RNA virus infection [71,72]. 
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3.3. Recognition of DNA Viruses 
The analysis of TLR ligands clearly shows that the endosomal TLR9 senses hypo/unmethylated 
CpG  DNA  that  is  present  in  genomes  of  bacteria  and  viruses.  TLR9  is  also  the  major  sensing 
mechanism for DNA viruses and TLR9 dependent recognition of virus infection results in production 
of  Type  I  IFN  [73].  Rather  unexpected  was  the  observation  that  TLR2  plays  a  critical  role  in 
recognition of herpes viruses.  In DC that expresses multiple TLR receptors, HSV-2 engaged both 
TLR2 and TLR9, but the TLR2 recognition was limited only to a distinct population of HSV-2 [74]. 
The synergistic interaction between TLR2 and TLR9 was also found to control HSV-2 infection in 
brain [75]. It has been assumed that TLR2 detects viral envelope glycoprotein [76]. 
As shown later, detection of viral DNA by cytoplasmic DNA sensors also leads to a profound 
antiviral  response,  and  multiple  cytoplasmic  DNA  sensors  have  been  identified  [77].  A  common 
feature of the signaling pathway induced by these receptors is activation of a transmembrane protein 
present on the endoplasmic reticulum designated STING (stimulator of IFN genes), which activates 
TBK-1 kinase that phosphorylates and activates IRF-3 and IRF-7 [78]. Redundancy may be another 
feature of these sensors. Thus DAI (DNA dependent activator of IRF) induces in vitro activation of 
Type  I  IFN in response to synthetic DNA and HSV infection by the TBK-1-IRF-3 axis, but DAI 
knockout mice did not show any attenuation of IFN induction [79,80]. Another DNA sensor, interferon 
induced protein 16 (IF16) also interacts with STING and activates the TBK-1-IRF-3 axis and Type I 
IFN production [81]. Two cytoplasmic sensors recognize AT-rich B form DNA. The first sensor is 
leucine rich repeat Fli-I interacting protein (LRRFIPI) that activates IFN production by association 
with  β  Catenin,  followed  by  recruitment  of  p300  histone  acetyltransferase  and  IRF-3  to  the  IfnB 
promoter  [77].  The  second  sensor  is  RNA  polymerase  III,  which  recognizes  AT  rich  DNA  and 
transcribes it to immunostimulatory RNA recognized by Rig  I [82]. The importance of these  two 
sensors for sensing viral infection remains poorly characterized. 
The response to DNA in the cytoplasm can also be mediated through inflammasome complexes, 
resulting in the production of inflammatory cytokines that are also an important part of the innate 
immune response [83]. Among these mediators is the protein AIM2 (absent in melanoma), which is an 
interferon induced protein that recognizes viral DNA and triggers the assembly of the inflammasome 
complex, resulting in activation of inflammatory cytokines IL1β and IL18, but not Type I IFN [77]. 
4. Interferon-Stimulated Genes: Mediators of the Antiviral Effects 
The Type  I IFN system has a critical role in the control of viral infection. Defects in the IFN 
system, in the genetically modified mice lacking functional type I IFN receptors and in humans with 
genetic defects in the type I IFN induction or response, result in inability to control viral infection 
[84,85] even in the presence of fully functional adaptive immune responses [86]. The antiviral effect of 
IFN is mediated by the induction of a large number of cellular genes (ISG) [87], which encode proteins 
with  diverse  functions  including  antiviral  properties,  pro-apoptotic  functions  and  modulation  of 
ubiquitination pathways [88]. Induction of these genes is initiated upon binding of Type I IFN to its 
cellular receptor, which initiates receptor-mediated signaling pathways involving the activation of two 
receptor  associated  kinases  (JAK1  and  Tyk2),  and  the  consequent  tyrosine  phosphorylation  of  Viruses 2011, 3                         
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pre-existing signal transducers and activators of transcription (STAT) [89]. Upon phosphorylation, 
STAT1 and STAT2 assemble together with interferon responsive factor 9 (IRF-9) into a multimeric 
complex  (ISGF3)  [90],  which  interacts  with  interferon-responsive  elements  (ISRE)  present  in  the  
5´ flanking region of ISG and activates their transcription [87,91]. Type I IFN also stimulates the 
formation of STAT1 homodimers, which bind to the IFN-γ-activated site (GAS), present in the ISG 
promoters that can be induced both by Type I IFN and  IFNγ [92]. In addition, the STAT2-IRF-9 
heterodimer is also an activator of ISG transcription. Signaling by Type I IFN also can activate both 
the MAPK and PI3K pathways [93], although the contribution of these two pathways to the antiviral 
response in vivo is not fully established.  
The antiviral function of the majority of ISG has yet to be determined. Several of the interferon-
induced antiviral pathways have been described, and the  component proteins have been identified 
[94,95].  The  earliest  characterized  ISG,  2´,5´-OAS,  induces  a  pathway  that  leads  to  viral  RNA 
degradation. Low levels of constitutive 2´,5´-OAS are up regulated by Type I IFN and when activated 
by  dsRNA,  the  2´,5´-OAS  enzyme  synthesizes  pppA(2´p5´A)n,  (2´,5´A  oligoadenylates),  which 
activate the cellular endonuclease, RNase L. Binding of 2’5’A oligoadenylates to RNAse L cleaves 
both cellular and viral RNAs at UU or AU nucleotides [96]. 
Constitutively expressed RNA dependent protein kinase (PKR) is also induced by Type I IFN. The 
inactive monomers are activated by binding viral RNA; PKR is subsequently phosphorylated and forms 
active dimers. Activated PKR dimers catalyze phosphorylation of several substrates including the α 
subunit of the initiation factor eIF-2 (eIF-2α) [97], as well as the transcription factor inhibitor IκB [98]. 
The Mx proteins are GTPases, which are induced by IFNα/β but not by IFNγ [99]. The Mx proteins 
accumulate  in  the  cytoplasm  or  endoplasmic  reticulum,  where  they  are  present  as  oligomers.  In 
infected cells, Mx monomers are released to the cytoplasm and bind essential viral components and 
then degrade them. Mx proteins confer  a high  degree of antiviral resistance to infection for large 
groups of viruses [100]. The role of the OAS, PKR, and Mx pathways in resistance to viral infection 
was clearly established in genetic studies; mice that are lacking any of these pathways have decreased 
resistance to viral infection. Surprisingly however, some antiviral resistance still remained in mice in 
which all three pathways were deleted indicating that not all the cell mediated resistance to virus 
infection is mediated by these three pathways [95,101]. 
Several additional ISG were shown to have antiviral functions. ISG15, one of the first identified 
ISG, is a ubiquitin-like protein that can be covalently attached to the lysine residues of viral  and 
cellular proteins, and thereby direct interplay between ubiquitination and ISGylation [102]. Many of 
the ISG 15 targeted proteins have an important role in the interferon system. Unlike ubiquitination, 
ISGylation does not target proteins for degradation but can prevent Ub mediated degradation. Thus 
ISG15 was show to interfere with the ubiquitination pathway essential for assembly and release of 
HIV-1 and Ebola virus virions [103,104] (see below).  
Type I IFN induced endonuclease ISG20, is specific for ssRNA. Furthermore, IFN induces two 
nucleic  acid  editing  enzymes,  adenosine  deaminase  (ADAR)  acting  on  RNA  and  APOBEC3G. 
ADAR-mediates transition of nucleotides from A to I, which disrupts base pairing and the AU base 
pair is replaced by the less stable IU pair that destabilizes dsRNA. This A-I editing has been found in 
multiple viral RNA sites of negative strand RNA viruses, and has been associated with persistent 
infection  [105].  APOBEC3G  is  a  cytosine  deaminase  that  converts  cytidine  to  uridine  in  single Viruses 2011, 3                         
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stranded  proviral  DNA,  which  results  in  hyper  mutation  of  the  HIV-1  genome.  Expression  of 
APOBEC3G  has  been  shown  to  be  up-regulated  by  IFNα  [106,107].  Thus  both  APOBEC3G  and 
ADAR are IFN-induced antiviral proteins, which can induce hyper mutation of the viral genome and 
decrease viral fitness. 
Finally, the role of IFN-induced miRNA in the antiviral response has been reported recently and 
their number and importance has been given high attention [108,109]. 
During the early days of IFN research, it was assumed that the interferon-mediated inhibition of 
viral replication was caused by a common mechanism affecting a large number of different viruses. 
Instead, it has become clear that the antiviral effect is due to the combinatory effects of many proteins, 
and any antiviral protein may show specificity for a distinct group of viruses. 
5. Viral Strategy to Overcome the Antiviral Response 
The  effective  antiviral  response  limits  the  ability  of  a  virus  to  replicate.  To  overcome  the  cell 
mediated block, most viruses developed mechanisms to eliminate the interferon function by acquiring 
genes encoding nonstructural proteins that are non-essential for viral replication but can block the 
antiviral IFN response. Since the capacity of viral genomes is limited, many of the viral antagonists 
simultaneously  inhibit  multiple  components  of  the  IFN  system,  thus  achieving  inhibition  of  the 
antiviral response by a limited number of proteins. Thus a single viral protein like paramyxovirus V 
protein targets both the critical  components in  the signaling pathways  leading to both type  I  IFN 
induction and IFN action [110,111]. The common strategies are the inhibition of IFN induction by 
targeting steps involved in IRF-3 activation [35,112] or promoting its degradation [113] and inhibition 
of Type I IFN signaling pathways by activation of the cellular suppressors of STAT, SOCS-1 and 3 
[114]. The large DNA viruses express several proteins that can inhibit the antiviral response using 
alternative approaches. Thus KSHV expresses several analogues of cellular IRF, vIRF1-4 that have 
dominant negative effects on cellular IRF [30,33,34,36]. Alternatively pox viruses encode soluble IFN 
receptors that compete with IFN for binding to cellular receptors [115]. 
Another viral approach to circumvent innate immunity, used preferentially by lytic viruses, is to 
inhibit a basic cellular mechanism such as synthesis of host RNA and proteins [116]. Taken together, 
these  data  indicate  that  the  ability  of  the  virus  to  establish  a  spreading  infection  depends  on  a  
well-controlled balance between the initial cellular antiviral response and the ability of the virus to 
overcome it.  
6. Role of the Innate Immune Response in HIV-1 Infection 
It has been well established that HIV-1 infection is associated with the modulation and activation of 
the immune system [117], characterized by a progressive decline and dysfunction of T cells, impaired 
function of NK cells, and polyclonal activation of B cells. The levels of immune activation are an 
indication of the progression of the HIV-1 disease. When the cytokine response induced during the 
early stages of HIV-1 was evaluated by the analysis of cytokine plasma levels or cytokine expression 
in PBMC, in most cases there was up-regulation of cytokines and chemokines including IFN, IL-1 and 
TNFα and decreased levels of IL-6 and IL-2. Furthermore, the expression of Type I IFNβ was transient 
and two consecutive peaks in cytokine levels were observed. The first peak, which occurred at about  Viruses 2011, 3                         
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6 days after the start of viremia, was transient and showed an increase in IFN-α, IL-15, TNF-α, IP-10, 
and MCP-1, and the second peak, associated with production of IL-6, IL-8, IL-10, IL-18, and IFN-γ, 
was detected 7 to 12 days post infection [118]. This data indicate that the early steps of HIV1 infection 
are associated with activation of the innate antiviral and inflammatory response prior to development 
of the adaptive immune response. Potential cross talk between innate and adaptive immunity in HIV-1 
pathogenicity and its mechanism has not been investigated in detail. The profound innate inflammatory 
response to HIV-1 infection leading to the induction of an antiviral response may also have detrimental 
effects. The expression of pro-inflammatory cytokines may promote HIV-1 replication and suppress 
the antiviral effect of Type I IFN. Stimulation of HIV-1 replication by TNFα and IL-6 was shown  
in vitro and may also occur in vivo [119]. Another factor of the innate immune system, IRF-1, was 
recently  implicated  in  the  regulation  of  HIV-1  infection.  IRF-1  is  expressed  constitutively  at  low 
levels, but its expression is strongly up-regulated by IFN γ. IRF-1 was also induced in T cells during 
early steps of HIV-1 infection [120] and the expression of IRF-1 was also observed in non-permissive 
HIV-1 infection of DC. In these cells, HIV-1 induced increased expression of IRF-1 and IRF-7, but the 
activation of IRF-3 was suppressed [121]. The 5’LTR region of HIV-1 contains an IRF-1 binding site, 
and its deletion impairs HIV-1 replication in vitro [122]. Interestingly, specific IRF1 polymorphisms 
have been found in a small group of people showing resistance to HIV-1 infection and pathogenicity 
(non progressors). This polymorphism was associated with the reduced levels of IRF-1 in PBMC, 
suggesting that the decrease in IRF1 expression may limit the susceptibility to HIV infection as IRF-1 
contributes to stimulation of HIV-1 replication [123]. 
The detrimental role for immune activation in HIV infection is supported by animal studies. In the 
pathogenic  SIV  animal  model  of  HIV,  induction  of  the  strong  innate  inflammatory  response  is 
characterized by production of Type I IFN during the very early stages of SIV infection; in contrast, in 
nonpathogenic SIV infection the induction of inflammation and Type I IFN is only transient [124].  
6.1. HIV-1 Infection in vitro Induces Interferon Signature 
In vitro, HIV-1 infects a number of diverse cell types; however the characteristics of the infections 
in these cells are distinct. Thus while infection in activated CD4+ T cells is productive and cytopathic, 
in naïve T cells HIV-1 is present in latent state. In macrophages HIV-1 replicates at low levels and 
does not induce cytopathic effects. Thus the innate antiviral response to HIV-1 infection in different 
cell types may be distinct. Several cell types, including CD4+ T cells, primary macrophages,  and 
PBMC, infected with HIV-1 in vitro induced interferon signature, while induction of either IFNα or 
IFNβ was generally difficult to detect. Analysis of this typical interferon signature transcription profile 
in HIV infected CD4+T cells showed significant up-regulation of expression of interferon stimulated 
genes  with  increasing  viral  load,  including  genes  of  the  intrinsic  antiretroviral  defense.  Upon 
successful antiretroviral treatment, the signature profile of previously viremic individuals reverted to a 
pattern comparable to that of non progressors and uninfected individuals [125]. In contrast, when the 
transcription profile of lymph nodes from HIV-1 infected patients was analyzed, only about 5% of the 
identified  genes  were  associated  with  the  antiviral  response  and  the  majority  of  the  genes  were 
negatively  associated  with  HIV-1  replication.  Based  on  these  data  the  authors  concluded  that  the 
antiviral  response  is  not  sufficient  to  attenuate  HIV-1  replication  [126].  Recent  data  have  shown  Viruses 2011, 3                         
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up-regulation of type I IFN induced ISG in activated HIV-1+CD4+ T cells [127], indicating that only a 
subset of CD4+ cells can induce IFNα. However the IFN signature induced in PBMC can be also 
induced by exogenous Type I IFN produced by other types of cells such as PDC, which are high 
producers of IFNα. The interaction between HIV-1 and DC is complex and not yet fully understood. It 
was shown that PDC are recruited to the site of HIV-1 replication in HIV-positive lymph nodes and 
this recruitment has been facilitated by expression of increased levels of lymphocyte homing marker 
CCR7 on circulating DC of HIV-1 infected individuals [128]. Activated DC from HIV-1 infected 
individuals expressed high levels of  IFNα  and other inflammatory  cytokines and these could well 
contribute to increased HIV-1 replication through immune activation. 
The mechanism and the signaling pathway by which HIV-1 activates IFN production in dendritic 
cells has been subject of intensive studies. The PDC are an essential part of the innate immune system 
and the major producer of  IFNα  It was shown that the co-culture of  PBMC with HIV-1 infected 
lymphocytes or infected CD4+ cells resulted in production of relative high levels of Type I IFN and 
that the major producers were the DC [118]. Production of IFNα was observed in lymph nodes of 
AIDS patients [128] and has been associated with disease progression [129,130]. Recent clinical data 
suggest that production of IFNα may drive the hyper activation of the immune system resulting in CD4 
T  cell  depletion  and  AIDS  [127].  Presently,  it  is  assumed  that  IFNα  alone  contributes  to  the 
progression of AIDS disease, however a decrease in CD4+T cells is also associated with a significant 
increase in serum levels of inflammatory cytokines including TNFα. IL-6, IL-18 and IL-7 which may 
contribute to the observed hyper activation of the immune system.  
The DC are generally resistant to HIV-1 infection, and co-culture of HIV-1 particles with monocyte 
derived dendritic cells (MDDC) neither infects DC or stimulates their activation. However when the 
freshly  isolated  DCs  were  infected  with  various  HIV-1  strains  in  vivo,  they  were  permissive  for 
productive infection with the macrophage tropic HIV-1 (R5 HIV-1) and the infected DCs transferred 
HIV-1 to CD4 T cells [131]. It was shown that DC and T cells can form conjugates that facilitate 
transfer of HIV-1 from DC to T cells [132]. It was also shown that this transfer is bi-phasic [133]. 
As described above, cell recognize RNA viruses either by the membrane bound receptors such as 
TOLL receptors or cytoplasmic receptors such as RNA helicase RigI and MDA5. Which of these 
receptors are engaged upon HIV-1 infection has not been fully explored. However it was shown that 
the peptide inhibitors of TLR7 ligands inhibited IFN production in PBMC co-cultivated with HIV-1 
infected T cells, indicating that the HIV-1 recognition is at least partially mediated by TLR7 [130,134]. 
The  TLR7  independent  pathway,  which  depends  on  IRF-3,  was  also  induced  in  the  co-culture 
experiments of HIV-1 infected T cells with TLR negative cells. Interestingly the induction of Type I 
IFN did not depend on HIV-1 replication in the infected cells, but was facilitated by the fusion of the 
infected T cells with DC [134]. It is possible that the fusion transfers large amounts of viral nucleic 
acids to the cytoplasm of DC, where the viral RNA may be recognized either by TLR7 or one of the 
cytoplasmic sensors such as Rig I or MDA5. Alternatively, the un-integrated proviral DNA could be 
recognized by one of the recently identified cytoplasmic DNA sensors. Further studies will certainly 
address these questions. 
Another  very  interesting  and  novel  aspect  of  the  mechanism  of  IFNα  induction  in  DC  is  the 
observation that the restriction of HIV-1 replication in DC can be overcome by the SIV encoded 
protein Vpx. Expression of this protein or co-infection with SIV (that encodes Vpx) allowed HIV-1 Viruses 2011, 3                         
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replication in DC, stimulated production of IFNα and activated DC [135]. It was also shown recently 
that  Vpx  induces  proteasomal  degradation  of  SAMHD1,  a  negative  regulator  of  the  interferon 
response.  Silencing  of  SAMHD1  in  non-permissive  cell  lines  alleviated  HIV-1  restriction  and 
overexpression of SAMHD1 in sensitive cells attenuated HIV-1 replication [136]. Further experiments 
demonstrated requirement of an interaction of HIV-1 capsid with CYPA for IFN production [135]. The 
induction of IFN was also dependent on nuclear localization of phosphorylated IRF-3. Whether the 
phosphorylation and activation of IRF-3 in these cells depends entirely on the capsid interaction with 
cellular proteins or whether the requirement for the capsid interaction is connected to the TLR3 or RIG 
I- IRF-3 axis needs yet to be clarified. However it is unlikely that the SAMHD1 is the only factor that 
can modulate HIV-1 replication in DC. The attenuation of HIV-1 replication by the intrinsic cellular 
antiviral proteins such as APOBECC3G, TRIM and others [95] may also contribute to this inhibition.  
6.2. Factors Counteracting the Antiviral Response to HIV-1 Infection 
In addition to the antiviral ISG described earlier, type I IFN induces expression of several ISGs that 
interfere with different stages of HIV-1 and retroviral replication. These proteins are constitutively 
expressed at low levels in a cells type specific manner, and unlike the antiviral enzymes PKR or 
2’5’OAS (already described above), they do not seem to require virus mediated activation (reviewed in 
[137,138].  The  first  of  these  cellular  factors,  dubbed  intrinsic  immunity  factors  was  APOBEC3G 
[139]. APOBEC3G is a cytidine deaminase that represses reverse transcription of viral RNA, acts on 
CC dinucleotide motifs and induces deamination of cytidine to uridine during synthesis of negative 
strand  proviral  DNA  transcripts.  This  change  leads  to  a  G  to  A  transition  in  proviral  DNA  and 
decreased ability (fitness) in virus replication. The expression of APOBEC3G is stimulated by Type I 
IFN [140], and depends on NFATc1/NFATc2 and IRF-4. When either NFATc1 or NFATc2 and IRF-4 
were co-expressed, activity of the APOBEC3G promoter was observed in cells that normally lack 
APOBEC3G  expression.  In  addition  to  its  effect  on  virus  fitness  APOBEC3G  editing  results  in 
misfolding  of  viral  proteins  and  enhances  their  recognition  by  CTL  cells,  thereby  stimulating  the 
antiviral adaptive immune response [141]. 
Type  I  IFN  effectively  induces  the  family  of  tripartite  motif  (TRIM)  proteins  that  also  restrict  
HIV-1 replication. TRIM5a from rhesus macaque (RhTRIM5a) blocks the early replication steps of 
HIV-1  and  other  retroviruses  [142]  by  targeting  the  incoming  viral  capsid  (CA)  protein  for 
degradation. Anti-HIV-1 activity has also been reported for TRIM1 that also targets the CA protein at 
an early stage of pre-reverse transcription. TRIM19 was suggested to affect trafficking of viral proteins 
[143], and TRIM22 blocked the release of HIV-1 Gag particles [144]. 
It was shown that Type I IFN inhibits both acute and chronic retroviral (MuLV) infection and that 
the inhibition was at the posttranslational level affecting virus assembly  and release [145]. HIV-1 
replication was found to be also sensitive to IFN inhibition, and the block was mapped to the late 
stages of HIV-1 replication [146]. IFNα induced antiretroviral activities also include a decrease in 
proviral DNA accumulation [147], restriction of viral entry and viral nucleic acid synthesis [148], and 
in macrophages Type I IFN restricts HIV-1 replication during the initial stages of infection [149].  
At least three  ISGs were shown to affect HIV-1 assembly  and release.  ISG15,  a ubiquitin-like 
protein inhibits HIV-1 infection [150] by interfering with the ubiquitination of HIV-1 Gag, blocking Viruses 2011, 3                         
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the interaction of TSG101 with Gag and consequently inhibiting the endosomal trafficking pathway, 
used by HIV-1 virions to exit cells [103]. The ISG 15 block is not specific for HIV-1, but also affects 
release of the Ebola virus particles [104]. TRIM22 blocks the intracellular trafficking of the  viral 
structural protein Gag to the surface of the cell. The antiviral activity of TRIM22 is dependent on the 
E3  ligase  activity  of  the  RING-containing  region  of  TRIM22  [144].  Finally,  the  cellular  protein  
BST-2, also known as tetherin, has been shown to be a very effective inhibitor of HIV-1 release [138]. 
This protein is expressed constitutively in DC and B cells, but can be also effectively induced by Type 
I  IFN  in  other  cell  types.  Unlike  the  trapped  retroviral  virions  in  IFN  treated  cells,  which  have 
decreased infectivity, the HIV-1 virions retained on the cell surface by tetherin are infectious. The 
tetherin  mediated  inhibition  is  not  specific  but  inhibits  release  of  a  large  group  of  retroviruses, 
filoviruses and herpes viruses [151,152]. 
Altogether these results indicate that HIV-1 can induce a strong innate immune response, associated 
with type I IFN mediated induction of several ISGs with a profound anti HIV-1 activity. Therefore the 
absence of the innate antiviral control of HIV-1 replication has been somewhat puzzling. One reason is 
that HIV-1, like the other RNA viruses, developed mechanisms by which it down-regulates the action 
of  the  antiviral  ISG.  HIV-1  encodes  three  small  accessory  proteins  Vif,  Vpr  and  Vpu,  which 
circumvent the innate immune response by targeting the cellular antiviral proteins APOBEC3G and 
tetherin for ubiquitin dependent proteasome degradation. The expression of Virion infectivity factor, 
Vif, is essential for HIV-1 replication in primary T cells [137]. In the absence of Vif, APOBEC3G is 
incorporated  into  HIV-1  virions;  thus  Vif  prevents  packaging  of  APOBEC3G  and  its  availability 
during the very early stages of HV-1 infection [153]. Virion associated viral protein R (Vpr) stimulates 
proviral transcription, and similar to SIV encoding Vpx, facilitates infection of macrophages. Both Vpr 
and Vif interact with cullin associated ubiquitin complex [137]. Vpr and Vif also target IRF-3 for 
degradation in T cells, which results in inhibition of the antiviral response and IFNβ synthesis [113]. 
Finally, the membrane protein, Vpu, is required for efficient release of virus particles. Vpu interacts 
with the trans membrane domain of tetherin and targets it for proteasomal or lyosomal degradation 
[154,155]. Virions of HIV-1 mutants lacking the vpu gene accumulate on the plasma membrane of 
infected cells and are not released to the medium. Vpu also interacts with CD4 and targets it for 
degradation by the cullin associated ubiquitin complex [156].  
Other  viral  encoded  functions  may  also  counteract  innate  immunity.  Interestingly,  the  negative 
factor Nef that has multiple functions, mostly in the modulation of adaptive immunity, can overlap 
Vpu and antagonize tetherin. In fact, primate SIV variants that lack Vpu use Nef to block the function 
of tetherin [157] (Figure 1). 
The role of HIV-1 encoded protease was recently shown to play a role in the inhibition of Rig I 
mediated signaling induced by in vitro synthesized HIV-1 RNA. Ectopic expression of HIV-1 protease 
resulted  in  inhibition  of  IRF-3  phosphorylation  and  induction  of  ISG  [158].  Since  it  is  not  clear 
whether ss HIV-1 RNA induces an interferon response in infected cells by the Rig I pathway, the  
in vivo relevance of this observation is yet to be confirmed. 
In  addition  to  virus  encoded  antiviral  factors,  several  cellular  proteins  also  contribute  to  
down-regulation of the HIV-1 induced antiviral response. Thus the cellular DNAse Trex1 degrades the 
unintegrated  proviral  DNA  in  infected  cells,  thus  preventing  its  detection  by  TLR9  or  by  the 
cytoplasmic  DNA  sensors.  In  TREX1  deficient  cells  HIV-1  DNA  accumulates,  which  leads  to Viruses 2011, 3                         
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induction  of  the  IFN  response  [159].  Interestingly  induction  of  IFN  required  the  cellular  adaptor 
STING and IRF-3, suggesting that proviral DNA is recognized by one of the cytoplamic DNA sensors, 
rather than by TLR9 [78]. Finally it was shown in SIV infected CNS macrophages, that IFNβ signaling 
is attenuated by induction of Suppressor of interferon signaling, SOCS3 [160]. Also the virus induced 
miRNA may modulate the antiviral response. In vitro studies have shown that several IFNβ induced 
miRNA including miR-26a, -34a, -145 targeted IFNB mRNA and attenuated the antiviral response 
[161].  Whether  these  miRNA  also  regulate  the  Type  I  IFN  system  in  HIV-1  infected  cells  
in vivo is yet to be determined. 
Figure 1. Schematic illustration of regulation of HIV-1 infection during innate antiviral response. 
 
7. Reflections and Future Considerations 
Recent studies have clearly established that type I IFN has not only a critical role in the innate 
antiviral response but also in the pathogenicity of viral infection. Presently, some aspects of virus 
mediated induction of type I IFN and cytokine genes are understood at molecular levels, while others 
are  still  at  a  descriptive  stage.  The  availability  of  genetically  modified  mice  lacking  essential 
components of the IFN signaling pathways confirmed that IFN is the earliest cellular defense against 
viral infection and a potent stimulant for the subsequent adaptive immune response. Rather unexpected 
was the observation that type I IFN induced large de-repression of the cellular genome stimulating 
expression of a large number of cellular genes, that are not only antiviral but are also involved in many 
different cellular functions. While it is easy to see the advantage generated by redundancy of antiviral 
proteins in their function against a wide variety of viruses, it is less evident why IFN evolved to control 
not only immune, but also many cellular functions. One has to wonder whether the multiplicity of IFN 
controlled genes reflect the number of cellular functions used by viruses for replication and survival. 
Important  insights  into  viral  pathogenicity  have  emerged  from  the  observation  than  some  of  the 
nonstructural viral proteins target components of the IFN system, thereby decreasing or eliminating the 
antiviral response.  
The innate antiviral response leads to expression of a large number of inflammatory cytokines in 
addition to interferon. The increased understanding of the cross talk of IFN pathway with the other Viruses 2011, 3                         
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inflammatory  cytokines,  illustrates  an  increasing  degree  of  complexity  in  the  mechanism  of  IFN 
action. This is well demonstrated in HIV-1 infection, where the early response to infection leads to a 
massive  inflammatory  response  consisting  of  production  of  type  I  IFN,  and  many  inflammatory 
cytokines. Thus while transient expression of type IFN may limit viral spread in the initial stages of 
infection, the cytokines stimulate HIV-1 infection either directly or by activation of immune cells. 
Since the ectopic expression of IFN inhibits HIV-1 replication in T cells [162], future studies will no 
doubt explore the means not only how to eliminate HIV-1 mimicry, but also how to generate the IFN 
response in the absence of inflammatory cytokines. 
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